drugset / Trial / NCT04704843

A Study of Guselkumab in Adult Participants With Celiac Disease

NCT04704843

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of guselkumab compared to placebo in participants with celiac disease.

Timeline

Start
2021-06-17
Primary completion
2021-09-13
Completion
2021-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody Intravenous

Indications